Aethlon Medical study flags Long COVID biomarker, supports Hemopurifier evaluation

Aethlon Medical, Inc.

AEMD

0.00

Aethlon Medical reported peer-reviewed Long COVID research published June 26, 2026 in the International Journal of Molecular Sciences; results were already presented in print.
The study identified a blood-based biomarker signal in Long COVID, supporting extracellular vesicles as a potential therapeutic target.
Laboratory work showed the Hemopurifier’s binding resin can capture the disease-associated vesicles, strengthening the case for future Long COVID studies.
Management kept near-term priorities on its Australian oncology clinical trial, positioning Long COVID work as a follow-on program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606260801PR_NEWS_USPR_____LA92970) on June 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.